药动学-药效学结合模型的研究进展及在新药研发中的应用

被引：49

作者：

柳晓泉

陈渊成

郝琨

曹彦光

余丹

机构：

[1] 中国药科大学药物代谢与动力学研究中心

来源：

中国药科大学学报 | 2007年 / 06期

关键词：

药动学; 药效学; 模型; 药物研发;

D O I：

暂无

中图分类号：

R96 [药理学];

学科分类号：

100706 [药理学];

摘要：

药动学-药效学(PK-PD)结合模型是综合研究药物在体内的动态变化过程与其药效消长之间关系的一种有力工具,它借助数学方法定量表述浓度(或剂量)、时间和效应三者之间的内在关系,对药物的研究开发及合理使用具有普遍的指导意义。PK-PD模型可按药动学与药效学联结方式的不同分成4种基本类型。近年来,神经网络技术、最优设计理论推动了具有多成分多靶点作用特征的PK-PD模型的发展。本文最后重点介绍了PK-PD模型在新药研发的临床前和临床阶段的应用以及当前研究热点,并对今后的发展趋势进行展望。

引用

页码：481 / 488

页数：8

共 19 条

[1]

Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO) [J].

Woo, Sukyung ;

Krzyzanski, Wojciech ;

Jusko, William J. .

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2007, 34 (06) :849-868

[2]

Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice [J].

Chen, Jin ;

Lu, Qiang ;

Balthasar, Joseph P. .

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2007, 34 (06) :829-847

[3]

Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects [J].

David Czock ;

Frieder Keller .

Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34 :727-751

[4]

Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society [J].

Cavero, Icilio .

EXPERT OPINION ON DRUG SAFETY, 2007, 6 (04) :465-471

[5]

Pharmacokinetics and pharmacodynamics of the interferon-betas; glatiramer acetate; and mitoxantrone in multiple sclerosis.[J].Oliver Neuhaus;Bernd C. Kieseier;Hans-Peter Hartung.Journal of the Neurological Sciences.2007, 1

[6]

A program for individual and population optimal design for univariate and multivariate response pharmacokinetic–pharmacodynamic models.[J].Ivelina Gueorguieva;Kayode Ogungbenro;Gordon Graham;Sophie Glatt;Leon Aarons.Computer Methods and Programs in Biomedicine.2007, 1

[7]

Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath<sup>®</sup>) in patients with chronic lymphocytic leukaemia and its link to treatment response.[J].D. R. Mould;A. Baumann;J. Kuhlmann;M. J. Keating;S. Weitman;P. Hillmen;L. R. Brettman;S. Reif;P. L. Bonate.British Journal of Clinical Pharmacology.2007, 3

[8]

Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling: Biophase Distribution; Receptor Theory; and Dynamical Systems Analysis.[J].Meindert Danhof;Joost de Jongh;Elizabeth C.M. De Lange;Oscar Della Pasqua;Bart A. Ploeger;Rob A. Voskuyl.Annual Review of Pharmacology and Toxicology.2007, 0

[9]

Optimal Design for Multiresponse Pharmacokinetic–Pharmacodynamic Models – Dealing with Unbalanced Designs [J].